Which genomic-sequencing leader wins in a head-to-head match-up?
Does a better product mean Pacific Biosciences is finally ready to take on Illumina?
What does Roche’s partnership termination with Pacific Biosciences mean for Illumina shareholders?
Here are three reasons to believe that the genomic-sequencing giant is poised to have a prosperous 2017.
Exact Sciences CEO discusses the company's huge opportunities at the J. P. Morgan Healthcare Conference.
Shares rally in response to a number of exciting announcements that were made at the 2017 J.P. Morgan Healthcare Conference.
Multiple analysts see multiple reasons to love the gene-sequencing pioneer.
Despite a lack of news, shares of the DNA sequencing champ are surging today. Could this be the reason?
For the second time in a week, this ticker's glowing red.
Pacific Biosciences stock fared poorly in 2016, but the New Year could make investors happier -- if the company does these three things.